Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotech firm Idenix Pharmaceuticals (Nasdaq: IDIX) jumped as much as 11.9% on higher-than-average trading volume.

So what: Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ) just partnered up to study a two-company drug cocktail to treat chronic hepatitis C. The giants hope to find an effective hep-C treatment that doesn't rely on interferons and other injections with severe side effects -- and Idenix's IDX184 happens to target exactly that market.

Now what: Already in phase 2b FDA trials, IDX184 is Idenix's greatest hope for a future blockbuster at the moment. The oral drug is designed to enhance the efficiency of other medications, which is why the stock jumped on today's news -- Idenix doesn't have a big-name partner for the endgame yet and might end up arm-in-arm with J&J or Bristol-Myers. The firm is no stranger to big-name collaborations, having licensed hepatitis B medication Tyzeka to Novartis (NYSE: NVS) for worldwide marketing.

Interested in more info about Idenix Pharmaceuticals? Click here to add it to My Watchlist.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.